A trend was evident, whereby patients in the top 2 tertiles of BST2 expression showed a shorter interval of disease-free survival compared to those with lower BST2 expression in the primary tumor (p = 0.12), supporting our in vitro molecular and functional studies on breast cancer cell lines. The gene discussed is BST2; the disease is neoplasm.